Context Therapeutics Inc CNTX

Healthcare

Context Therapeutics Inc. is a biopharmaceutical company focused on improving the lives of patients living with solid tumors. The Company is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors. Its preclinical program, CTIM-76, is an anti-Claudin 6 x anti-CD3 (CLDN6xCD3) antigen bispecific monoclonal antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, lung, and testicular, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is a Claudin 6 and CD3 bispecific antibody capable of binding to tumor cells expressing Claudin 6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement. Claudin 6 is expressed on multiple solid tumors such as ovarian, lung and testicular.

NDAQ:CNTX - Post by User

Context Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

(6)
•••

Post by Shanemorg58on Jan 06, 2023 11:10am

34 Views

Post# 35206873

Strong Hold!

https://www.edisongroup.com/publication/a-catalyst-rich-period-ahead/31836/
the company is making really good progress in advancing both of its pipeline assets, and not to mention presenting encouraging preliminary data from its ongoing studies!

<< Previous

Bullboard Posts

Next >>

Copper is on the rise and this company could be your gateway into the market